Harrow’s (HROW) Buy Rating Reaffirmed at HC Wainwright

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $57.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 117.47% from the stock’s previous close.

Separately, B. Riley lowered their target price on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

Harrow Trading Down 6.0 %

NASDAQ:HROW opened at $26.21 on Monday. Harrow has a 12 month low of $9.86 and a 12 month high of $59.23. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock has a market capitalization of $933.47 million, a price-to-earnings ratio of -27.88 and a beta of 0.69. The firm has a fifty day simple moving average of $28.90 and a two-hundred day simple moving average of $37.97.

Harrow (NASDAQ:HROW) last issued its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The company had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. Analysts expect that Harrow will post -0.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Harrow

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Harrow by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock worth $62,809,000 after purchasing an additional 5,225 shares during the last quarter. Braidwell LP grew its holdings in Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company’s stock worth $30,431,000 after buying an additional 467,401 shares in the last quarter. State Street Corp raised its position in Harrow by 2.2% in the 3rd quarter. State Street Corp now owns 730,973 shares of the company’s stock valued at $32,865,000 after buying an additional 15,554 shares during the last quarter. Geode Capital Management LLC lifted its stake in Harrow by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock valued at $32,500,000 after acquiring an additional 3,960 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in Harrow by 6.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company’s stock valued at $22,301,000 after acquiring an additional 41,896 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.